2025
Suppression of endothelial ceramide de novo biosynthesis by Nogo-B contributes to cardiometabolic diseases
Rubinelli L, Manzo O, Sungho J, Del Gaudio I, Bareja R, Marino A, Palikhe S, Di Mauro V, Bucci M, Falcone D, Elemento O, Ersoy B, Diano S, Sasset L, Di Lorenzo A. Suppression of endothelial ceramide de novo biosynthesis by Nogo-B contributes to cardiometabolic diseases. Nature Communications 2025, 16: 1968. PMID: 40000621, PMCID: PMC11862206, DOI: 10.1038/s41467-025-56869-9.Peer-Reviewed Original ResearchConceptsNogo-BEndothelial dysfunctionHFD miceCardiometabolic diseasesSphingolipid signalingDevelopment of therapeutic strategiesBioactive sphingolipidsCeramide degradationSphingosine-1-phosphateHepatic glucose productionIn vivo evidenceEndothelial cellsEndothelial specific deletionCeramideBiosynthesisHigh-fat dietPathological implicationsSphingolipidsGlucose productionHFDIn vivoMale miceMetabolic dysfunctionTherapeutic strategiesMetabolic disorders
2013
Neural Crest Cells Isolated from the Bone Marrow of Transgenic Mice Express JCV T-Antigen
Gordon J, Sariyer I, De La Fuente-Granada M, Augelli B, Otte J, Azizi S, Amini S, Khalili K, Krynska B. Neural Crest Cells Isolated from the Bone Marrow of Transgenic Mice Express JCV T-Antigen. PLOS ONE 2013, 8: e65947. PMID: 23805194, PMCID: PMC3689770, DOI: 10.1371/journal.pone.0065947.Peer-Reviewed Original ResearchConceptsT-antigen-positive cellsProgressive multifocal leukoencephalopathyBone marrowJC virusJC virus T antigenPositive cellsMesenchymal stem cellsNeural crest characteristicsT antigenFraction of bone marrow cellsT-antigen transgenic miceStem cellsJC virus latencyBone marrow-derived stem cellsJC virus infectionJCV early proteinsMarrow-derived stem cellsPersistent viral infectionBone marrow cellsNon-hematopoietic lineagesDevelopment of therapeutic strategiesT-antigen expressionEarly gene expressionJCV T-antigenNon-hematopoietic mesenchymal stem cells
2012
Overcoming castration resistance in prostate cancer
Tsao C, Small A, Galsky M, Oh W. Overcoming castration resistance in prostate cancer. Current Opinion In Urology 2012, 22: 167-174. PMID: 22472508, DOI: 10.1097/mou.0b013e3283523b8b.Peer-Reviewed Original ResearchConceptsCastration resistanceProstate cancerTreatment of castration-resistant prostate cancerMechanisms of castration resistanceCastration-resistant prostate cancerPhase III clinical trialsAndrogen-signaling axisSecondary hormonal agentsAdvanced prostate cancerLandscape of treatmentIII clinical trialsDevelopment of therapeutic strategiesDocetaxel chemotherapyHormonal agentsClinical studiesClinical trialsTherapeutic strategiesTherapeutic opportunitiesCancerProstateSignaling pathwayClinical researchCastrationTreatmentMDV3100
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply